Beyond Air Inc

NASDAQ:XAIR   3:59:40 PM EDT
5.33
0.00 (0.00%)
Products

Beyond Air Submits Premarket Approval Application To FDA For Lungfit PH To Treat Persistent Pulmonary Hypertension Of The Newborn

Published: 11/11/2020 12:46 GMT
Beyond Air, Inc. (XAIR) - Beyond Air® Submits Premarket Approval Application to FDA for Lungfit™ Ph to Treat Persistent Pulmonary Hypertension of the Newborn.
Beyond Air Inc - Anticipate U.S. Commercial Launch for Lungfit Ph in Q2 of 2021.